

Haematologica
HAEMATOL/2016/151126
Version 3

Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis

John O. Mascarenhas, Moshe Talpaz, Vikas Gupta, Lynda M. Foltz, Michael R. Savona, Ronald Paquette, A. Robert Turner, Paul Coughlin, Elliott Winton, Timothy C. Burn, Peter O'Neill, Jason Clark, Deborah Hunter, Albert Assad, Ronald Hoffman, and Srdan Verstovsek

Disclosures: Conflict-of-interest disclosure: All study investigators institutions received research funding from Incyte Corporation for conduct of the study. J.O.M.: Incyte Corporation: Consultancy, Research funding; Novartis: Research funding; Roche: Research funding. M.T.: Ariad: Consultancy, Research funding, Travel reimbursements; Sanofi: Research funding; Pfizer, Consultancy, Research Funding, Travel reimbursements; Incyte Corporation: Research funding, Travel reimbursements; Novartis: Consultancy, Research funding, Travel reimbursements. V.G.: Incyte Corporation: Research funding, Honoraria; Novartis: Consultancy, Research funding, Honoraria, Advisory board participation. L.M.F.: Gilead: Research funding; Incyte Corporation: Research funding; Novartis: Consultancy, Advisory board participation; Research funding, Honoraria; Promedior: Research funding. M.R.S.: Incyte Corporation: Advisor/board member, Grants/research support; TG Therapeutics: Grants/research support; Amgen: Advisor/board member; Sunesis: Grants/research support, Karyopharm: Consultant/independent contractor, Advisor/Board Member; Ariad: Advisor/board member; Celgene: Advisor/board member; Gilead: DSMB member; CTI Pharma: Advisor/board member. R.P.: Incyte Corporation, Speaker. A.R.T.: Incyte Corporation, Research support; Novartis, Research support; Bristol-Myers Squibb: Research support. P.C.: Bayer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Eastern Health: Employment. E.W.: Incyte Corporation, Consulting/Advisory Board participation, Research funding; Gilead, Research funding; Promedior, Research funding; Pfizer, Research funding. D.H.: Incyte Corporation, Employment and stock ownership. A.A.: Incyte Corporation, Employment and stock ownership. J.C.: Incyte Corporation, Employment and stock ownership. T.C.B.: Incyte Corporation, Employment and stock ownership. P.O.: Incyte Corporation, Employment and stock ownership. R.H.: All Cells LLC: Consultancy, Membership on an entity's Board of Directors or advisory committees; Geron: Consultancy, Membership on an entity's Board of Directors or advisory committees. S.V.: AstraZeneca: Research funding; BMS: Research funding; Celgene: Research funding; CTI BioPharma Corp: Research funding; Geron: Research funding; Gilead: Research funding; Incyte Corporation: Research funding, Advisory board participation; Lilly: Research funding; NS Pharma: Research funding; Pfizer: Research funding; Promedior: Research funding; Roche: Research funding; Seattle Genetics: Research funding.

Contributions: John O. Mascarenhas, Moshe Talpaz, Vikas Gupta, Lynda M. Foltz, Michael R. Savona, Ronald Paquette, A. Robert Turner, Paul Coughlin, Elliott Winton, Ronald Hoffman, and Srdan Verstovsek were involved in the care of patients, collecting data, analysis and interpretation of data, collaborating on writing the manuscript, and approval of the final draft. Timothy C. Burn, Peter O'Neill, Jason Clark, Deborah Hunter, and Albert Assad were involved in the study conception/design, analysis and interpretation of data, collaborating on writing the manuscript, and approval of the final draft.